OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition

Condition:   Malignant Pleural Mesothelioma Intervention:   Drug: OT-101 Sponsor:   Oncotelic Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials